MURA Share Price Performance
Recent MURA News & Updates
No updates
Mural Oncology plc Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -7.57
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Mural Oncology plc Competitors
About MURA
- Founded
- 2017
- Employees
- 104
- CEO
- WebsiteView website
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Irish Market Performance
- 7 Days: 0.6%
- 3 Months: 10.8%
- 1 Year: 18.2%
- Year to Date: 18.4%
In the last week, the market has stayed flat, however the Healthcare sector stood out, gaining 4.0%. Meanwhile, the market is actually up 18% over the past year. Earnings are forecast to grow by 6.1% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading